DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for epithelioid hemangioendothelioma — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEpithelioid hemangioendothelioma maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for epithelioid hemangioendothelioma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CREB binding lysine acetyltransferase (CREBBP) — CREBBP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1vudrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9H0K · 1.75 Å · ligand propionyl Coenzyme A (1VU). Experimental structure, not a prediction.
What the evidence adds up to
Hepatic epithelioid haemangioendothelioma is a rare, low-grade malignant vascular tumour with non-specific clinical symptoms and laboratory findings; diagnosis requires histopathological investigation. The primary treatments are radical hepatic resection or liver transplantation, but the role of any adjuvant therapy remains undetermined. A 2025 case report describes a 40-year-old man with large hepatic masses and pulmonary nodules whose diagnosis was confirmed by endothelial marker positivity; because of the extent of disease, systemic therapy was planned, though no specific drug or regimen is named in the abstract.
For pulmonary epithelioid haemangioendothelioma, no reliably effective systemic chemotherapy has been established. Surgery is typically used for patients with a small number of lesions confined to one lung, but its feasibility, efficacy and safety are controversial for bilateral multiple lung lesions. The disease’s variable course — some cases show rapid aggravation, others very gradual progression — makes it difficult to evaluate surgery’s validity as a therapeutic approach.
No abstract reports a controlled trial, a response rate, a survival figure, or a specific drug tested in this disease. The 2010 and 2017 reviews explicitly state that the role of adjuvant therapies is undetermined and that no effective systemic chemotherapy exists. The 2025 case report mentions planning systemic therapy but gives no outcome data.
What is still missing are prospective trials with sufficient sample sizes, given the tumour’s rarity; validated biomarkers to stratify patients by risk of rapid versus indolent progression; and funding to test any systemic agent in a controlled setting. Without these, the evidence base for any drug in epithelioid haemangioendothelioma remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Zhonghua gan-dan waike zazhi · 2010 · 0 citations
Advancement in researches of diagnosis and treatment of hepatic epithelioid haemangioendothelioma
AbstractHepatic epithelioid hemangioendothelioma is a rare and low-grade malignant tumor of vascular origin.Clinical symptoms and laboratory findings are unspecific.The definitive diagnosis can only be made by histopathalogi-cal investigation The primary treatments of choice are radical hepatic resection or liver transplantation. The role of differ-ent adjuvant therapies for patients with hepatic epithelioid hemangioendothelioma remains to be determined.
Key words:
Hepatic; Epithelioid; Haemangioen-dothelioma
Medical Research Archives · 2017 · 0 citations · open access
Is bilateral multiple lung tumor resection an acceptable therapeutic option for pulmonary epithelioid hemangioendothelioma?
AbstractPulmonary epithelioid hemangioendothelioma is a rare pulmonary neoplasm. No reliably effective systemic chemotherapy for this disease entity has been established yet. Surgery is usually applied for patients with a small number of lesions limited to one lung, while feasibility/efficacy/safety of this modality is controversial for patients with bilateral multiple lung lesions. Presence of cases showing rapid aggravation and those showing very gradual progression makes it difficult to evaluate validity of surgery as a suitable therapeutic approach. Herein, we present a summary on pulmonary epithelioid hemangioendothelioma and discuss the role of surgery in the treatment of this condition.
Hepatic Epithelioid Hemangioendothelioma: A Rare Vascular Neoplasm of the Liver
AbstractEpithelioid hemangioendothelioma (EHE) is a rare vascular neoplasm that can involve multiple organs. Most cases are asymptomatic and detected incidentally, but the clinical course can vary significantly. A 40-year-old man presented with abdominal and chest pain; imaging revealed large hepatic masses along with pulmonary nodules. Histopathological examination confirmed the diagnosis of EHE, with positivity for endothelial markers. Given the extent of the disease, systemic therapy was planned. This case highlights the challenges in diagnosing EHE and underscores the need for an individualized approach to managing this rare tumor.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
